A range of prognostic factors have been identified for patients with glioma WHO grade III and glioblastoma, including age, WHO PS, extent of surgery, postoperative treatment, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, and isocitrate dehydrogenase (IDH) mutation [26–34]. Here, MGMT is linked to central nervous system cancer.